Successful treatment of kaposiform hemangioendothelioma with everolimus

There is currently no consensus on the second- line managementof Kaposiform hemangioendothelioma(KHE) that was resistant to prednisoloneand vincristine. We described an eight-year-old male with KHE in the right femur that was resistant to prednisolone, vincristineand propranolol. Everolimus, an inhibitor of mammalian target of rapamycin (mTOR) at the dosage of 0.1 mg/kg/day, successfully decreased the tumor size and controlled the symptoms. Everolimusshould be further studied as an alternative agent to sirolimusin the management of KHE.